🔗 Permalink

Inventor profile of:

Gavin MacBeath

City:

Wakefield, Massachusetts

Country:

United States

Published Applications:

Last publication date:

2025-09-18

Top Assignees for applications by Gavin MacBeath

The entities that hold a legal rights for patent applications filed by inventor MacBeath Gavin:

MERRIMACK PHARMACEUTICALS, INC. 5 Cambridge, MA United States
President and Fellows of Harvard College 2 Cambridge, MA United States
SANOFI 1 Paris, France
Merrimack Phamaceuticals, Inc. 1 Cambridge, MA United States

Recent patent applications by MacBeath Gavin

Gavin MacBeath from Wakefield, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-09-18

US20250288675A1

Human necessities

MULTIPLEXED T CELL RECEPTOR COMPOSITIONS, COMBINATION THERAPIES, AND USES THEREOF

#2 | 2025-08-07

US20250249039A1

Human necessities

PRAME IMMUNOGENIC PEPTIDES, BINDING PROTEINS RECOGNIZING PRAME IMMUNOGENIC PEPTIDES, AND USES THEREOF

#3 | 2024-06-20

US20240197877A1

Human necessities

BINDING PROTEINS RECOGNIZING HA-2 ANTIGEN AND USES THEREOF

#4 | 2024-06-13

US20240190931A1

Chemistry; metallurgy

MAGEC2 IMMUNOGENIC PEPTIDES, BINDING PROTEINS RECOGNIZING MAGEC2 IMMUNOGENIC PEPTIDES, AND USES THEREOF

#5 | 2023-12-14

US20230398217A1

Human necessities

BINDING PROTEINS RECOGNIZING HA-1 ANTIGEN AND USES THEREOF

#6 | 2023-12-14

US20230398205A1

Human necessities

SARS-COV-2 IMMUNODOMINANT PEPTIDE CONSTRUCTS AND USES THEREOF

#7 | 2023-09-14

US20230287390A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR IDENTIFYING EPITOPES

#8 | 2023-08-31

US20230272049A1

Chemistry; metallurgy

BINDING PROTEINS RECOGNIZING HPV16 E7 ANTIGEN AND USES THEREOF

#9 | 2023-08-03

US20230241205A1

Human necessities

SARS-COV-2 IMMUNODOMINANT PEPTIDES AND USES THEREOF

#10 | 2018-01-04

US20180002754A1

Chemistry; metallurgy

FRIZZLED 2 AS A TARGET FOR THERAPEUTIC ANTIBODIES IN THE TREATMENT OF CANCER

#11 | 2017-10-26

US20170306415A1

Chemistry; metallurgy

PREDICTING TUMOR RESPONSES TO ANTIBODIES AGAINST HEPATOCYTE GROWTH FACTOR (HGF) AND/OR ITS COGNATE RECEPTOR, C-MET

#12 | 2017-09-21

US20170267767A1

Chemistry; metallurgy

Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapies

#13 | 2017-07-27

US20170210810A1

Chemistry; metallurgy

BIOMARKER PROFILES FOR PREDICTING OUTCOMES OF CANCER THERAPY WITH ERBB3 INHIBITORS AND/OR CHEMOTHERAPIES

#14 | 2017-04-13

US20170101480A1

Chemistry; metallurgy

Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors

#15 | 2016-10-20

US20160303232A1

Human necessities

COMBINATION TREATMENTS WITH SERIBANTUMAB

#16 | 2016-07-28

US20160215343A1

Chemistry; metallurgy

Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer

#17 | 2016-03-31

US20160090418A1

Chemistry; metallurgy

Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapies

#18 | 2015-08-20

US20150231238A1

Human necessities

OVERCOMING RESISTANCE TO ERBB PATHWAY INHIBITORS

#19 | 2014-09-04

US20140248280A1

Human necessities

ANTI-ERBB3 ANTIBODIES IN COMBINATION WITH PACLITAXEL FOR TREATMENT OF GYNECOLOGICAL CANCERS

#20 | 2014-08-28

US20140242070A1

Chemistry; metallurgy

Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer

InventorID:

888113 ⎘